Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01669174 · ClinicalTrials.gov registry record · Phase 2
BYM338 in Chronic Obstructive Pulmonary Disease (COPD) Patients With Cachexia
A Phase 2 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 67
- Enrollment target
NCT01669174 is a Phase 2 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 67 participants.
The verdict
NCT01669174, a Phase 2 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 67 participants
- Enrollment target
Study Summary
This study will assess the pharmacodynamics, pharmacokinetics, safety and tolerability of BYM338 in patients with COPD and cachexia. The primary outcome will be a change in thigh muscle volume compared to placebo. The study will last for approximately 24 weeks.
Interventions
- DRUG Placebo
- DRUG BYM338
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 67 participants |
| Start Date | 2012-09 |
| Est. Completion | 2014-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01669174
The ClinicalTrials.gov registry entry for NCT01669174 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 67 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01669174 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01669174 about?
NCT01669174 is a clinical study titled "BYM338 in Chronic Obstructive Pulmonary Disease (COPD) Patients With Cachexia". This study will assess the pharmacodynamics, pharmacokinetics, safety and tolerability of BYM338 in patients with COPD and cachexia. The primary outcome will be a change in thigh muscle volume compared to placebo. The study will last for approximately 24 weeks.
What is the current status of trial NCT01669174?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 67 participants. The study started on 2012-09. Estimated completion is 2014-12.
What interventions are being tested in trial NCT01669174?
The interventions under investigation include: Placebo (DRUG), BYM338 (DRUG).
Who is sponsoring clinical trial NCT01669174?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.